For example, genomic alterations in c-MYC, FOXO1 or the androgen receptor (AR) have been described in neuroblastoma, breast, and prostate cancer, respectively (Bushweller 2019; Yu et al., 2019). This evidence concerns the gene AR and neuroblastoma.